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The Effect of Mycophenolate Mofetil on Early
Wound Healing in a Rodent Model
Martine CM Willems, MD,1 Thijs Hendriks, PhD,1 Roger MLM Lomme, BSc,1 Ben M de Man, BSc,1
and J Adam van der Vliet, MD, PhD1
Background. Immunosuppressant agents are inevitable for solid organ recipients, but may have a negative effect on
wound healing that is difficult to measure because of clinical use of a polydrug regime. The evidence on mycophenolate
mofetil (MMF) is scarce and contradictory. This study aims to investigate the effect of MMF administration on wound healing.
Methods. Ninety-six male Wistar rats divided into 4 groups underwent anastomotic construction in ileum and colon at day 0.
Three groups received daily oral doses of 20 or 40mg/kgMMF or saline (control group) from day 0 until the end of the experiment.
Half of each group was analyzed after 3 days and half after 7 days. Another group started the medication 3 days after the laparot-
omy andwas analyzed after 7 days, half of this group received 20mg/kg and half 40mg/kgMMF.Wound strength in anastomoses
and in the abdominal wall was measured using bursting pressure, breaking strength, and histology. Trough levels were measured.
Results. Significant differences in wound strength were seen in ileum tissue after 3 days, which surprisingly showed a stronger
anastomosis in the experimental groups. Bursting pressure as well as breaking strength was higher in the low-dose and high-
dose MMF group compared with the control group. A negative effect was measured in abdominal wall tissue for the highest-dose
group, which disappeared when the medication was delayed for 3 days. Histology showed poorer bridging of the submucosal
layer and more polymorphonuclear cell infiltration in the ileum specimens of the control group compared with the treatment groups.
Conclusions. As a single agent in a preclinical wound healing model in the rat, MMF has no negative effect on healing of bowel
anastomoses but might have a negative effect on the healing of abdominal wall.
(Transplantation Direct 2016;2: e80; doi: 10.1097/TXD.0000000000000591. Published online 20 May 2016.)
Due to a steady rise in numbers of solid organ transplan-tation, as well as a marked increase in efficacy and
safety of the immunosuppressant treatment scheme, recipi-
ents of solid organs rise in number and age. In fact, the num-
ber of people living with a functioning kidney transplant in
the United States doubled between 1995 and 2004 and al-
most doubled again by the end of the year 2012. This rise
can not only be due to the rise in total numbers of kidney
transplants and therefore represents the cumulative effect of
a better long-term outcome in past decades.1,2 Side effect of
this development is the fact that surgeons are increasingly
confronted with transplant patients in need of an operation,
either related to their transplanted organ or to other diseases,
such as aneurysms or malignancies,3–6 because it is well es-
tablished that solid organ recipients are at a higher risk of
developing malignancies compared to the general popula-
tion.5-7 Immunosuppressant therapy is presently inevitable
in solid organ recipients, and most drugs in the polydrug
regimen of medication have been associated with wound
healing complications. Awell-known regimen of immuno-
suppressant drugs in solid organ transplantation consists
of a calcineurine inhibitor such as tacrolimus or cyclospor-
ine (CsA), an antiproliferative agent such as mycopheno-
late mofetil (MMF) or azathioprine and a steroid. With
different immunosuppressant regimens, wound complica-
tions of the initial organ transplant operation have been re-
ported up to 52%.8-12
Many clinical studies have been carried out to identify im-
munosuppressant drugs with a high complication rate.8–12
However, it is difficult to entangle the effects on wound
healing in a clinical study, where a polydrug study regimen
is used. Furthermore, most clinical studies report adverse
events, without consistent focus on wound healing complica-
tions. Despite all this, cumulating evidence has led to some
modifications in clinical practice. In recent years, loading
doses of mammalian target of rapamycin (mTOR) inhibitors,
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such as sirolimus and everolimus, are avoided if possible in
the light of the wound healing complications. An increasing
awareness of the risks of wound complications of mTOR in-
hibitors has limited its use in the immediate postoperative
phase. In this light, it is important to know the effect on
wound healing of the other agents that are frequently used
in the direct postoperative phase.
MMF has been used as immunosuppressant for more than
a decade. It is also frequently used to treat acute rejection
after transplantation. MMF efficacy is attributed to its in-
hibitory activity on lymphocyte functions. After oral admin-
istration, MMF is rapidly absorbed and then converted to
mycophenolic acid (MPA)which is the active immunosuppres-
sant. MPA inhibits the activity of inosine monophosphate de-
hydrogenase (IMPDH), a rate-limiting enzyme for the novo
synthesis of guanosine nucleotides. Both adenosine and gua-
nine are derived from inosine monophosphate (IMP) which
is the first compound in the pathway to have a completely
formed purine ring system. The function and proliferation of
lymphocytes is more dependent on de novo purine nucleotide
synthesis compared with other cell types; therefore, IMPDH
inhibitors may provide a more lymphocyte-targeted immu-
nosuppression. By depleting the intracellular concentration
of guanosine nucleotides, MPA acts as a potent inhibitor of
lymphocyte proliferation.
Roos et al13 have demonstrated that MMF inhibits colla-
gen gene expression and fibroblast migration. Preclinical
studies with this drug have been carried out in vitro13,14 as
well as in pulpal tissue healing in dogs.15 Awell-known and
validated preclinical model for wound healing is a bowel
anastomose model in rats. Earlier studies have measured a
negative effect of MMF on the healing of bowel anastomo-
ses.16,17 However, an intractable difference in the regime of
these studies with the clinical situation is the fact that in these
studies MMF is started at days 3 and 7 before the operation,
whereas in humans, immunosuppressant drugs start immedi-
ately after the transplantation operation. It is clinically rele-
vant to find out if a negative effect on wound healing of
MMF exists when starting MMF at the day of operation.
In case of a negative effect ofMMFonwound strength, it will
be interesting to find out if any persistence of the effect is
measured when delaying MMF for 3 days, as we have mea-
sured in a different experiment with Everolimus, in the same
bowel anastomosis model.18
MATERIALS AND METHODS
Ninety-six male Wistar rats (body weight, 240-260 g;
Harlan, Horst, the Netherlands) were randomly divided into
4 groups of 24 animals. The animals were housed 2 per cage
and allowed to become accustomed to laboratory conditions
for 1 week before the start of the experiment. All animals
had free access to water and standard rodent chow (Ssniff
Specialdiäten GmbH, Soest, Germany). Two groups (groups
MMF20-0 andMMF 40-0) receivedMMF (Cellcept, Roche,
Woerden, the Netherlands) orally in daily dosages of 20 and
40 mg/kg from the day of operation to the end of the exper-
iment. Another group started the study medication on day
3 instead of day 0. Half of these animals received 20 mg/kg,
and half received 40 mg/kg MMF daily until the end of the
experiment (groups MMF20-3 and MMF 40-3.) A control
group of 24 animals received saline orally from the day of op-
eration until the end of the experiment. The study was
approved by the Animal Ethics Review Committee of the
Radboud University Nijmegen.
Surgical Procedure
On day 0, a laparotomy was performed under general an-
esthesia using isoflurane 3%, in a mixture of oxygen and
nitrous oxide. Amidline laparotomywas followed by a resec-
tion of 1 cm ileum, 15 cm proximal to the ileocaecal junction,
and 1 cm colon 3 cm proximal to the rectal peritoneal reflec-
tion. End-to-end anastomoses were constructed with 8 single-
layer, inverting, interrupted 8-0 ethilon (Ethicon) sutures. The
abdominal fascia was closed with an absorbable, polygalactin
3-0 suture, the skin was closed with staples. A heating pad
was used to maintain body temperature at 38°C. The intes-
tines were covered with gauze pads soaked with 0.9% NaCl
to minimize desiccation. Fluid loss was compensated by ad-
ministering 10 mL of 0.9% sodium chloride subcutaneously
directly postoperatively. Postoperative analgesia was performed
with buprenorphine, 0.02 mg/kg subcutaneously, twice daily
for 2 days. The animals were weighed daily and observed for
signs of illness. All operative procedures were performed by
the same investigator (M.W.).
Wound Strength
Of the control group and of the MMF-20-0 and MMF-
40-0 groups, 12 rats were killed on day 3 and 12 rats on
day 7 postoperatively. Of the groups with delayed medica-
tion, all rats were killed on day 7 postoperatively. The ani-
mals were killed by CO/CO2 asphyxiation. Relaparotomy
was performed by excision of a part of the abdominal wall
of approximately 4 by 4 cm, including the suture line of the
fascia. The anastomoses of ileum and colon were resected
with adjacent bowel of approximately 4 cm in length and
the suture line in the middle. The intestinal segments were
carefully resected, including surrounding tissues and adhe-
sions, and washed in saline. Bursting pressure and breaking
strength were measured in the same segment as described
previously.19 In the abdominal wall, breaking strength was
measured in the same way; from each segment of the abdom-
inal wall, 2 separate strips of 1 by 2 cm were collected, with
the suture line in the middle, and breaking strength was mea-
sured in both. The measurement of the least strong segment
was used. In each group, 2 rats were used for hematoxylin-
eosin staining and histologic description. After biomechani-
cal analysis, segments were cleaned from adhering tissue
and standard sized samples containing the suture line were
frozen in liquid nitrogen and stored at −80°C until further
processing.
Histology
Intestinal samples of approximately 1-cm length contain-
ing the anastomosis in the middle were carefully resected en
bloc, opened at the mesenteric side, and washed gently in
0.9% NaCl. They were spread out and immobilized, and
the samples were immediately fixed in 4% (v/v) phosphate-
buffered formaldehyde, pH 7.3. Each anastomosis was divided
into 2 or 3 longitudinal strips. Specimens were dehydrated and
embedded in paraffin. Sections of 4 mm in thickness were
stained with hematoxylin and eosin. Sections were analyzed
and assessed by histological parameters for anastomotic re-
pair as described before.20
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Of 4 rats in each of the following groups: control, MMF
20-0, and MMF 40-0 blood was sampled to determine
trough levels of MPA. Because we did not need to sample
blood for other reasons, we chose to sample blood by direct
heart puncture when the animals were killed for humane rea-
sons. MPA levels were determined by high performance liq-
uid chromatography, the detection limit was 0.4 mg/mL.
Statistical Analysis
Trough levels are expressed as mean ± standard deviation.
To analyze differences in body weight, a 1-way analysis of
variance was used. The software used for statistical analysis
was SPSS 23.0. For testing normality, the Shapiro-Wilk test
was used. Differences of bursting inside or outside the suture
line of the anastomosis were analyzed with Fisher exact test.
Data of breaking strength and bursting pressure were ana-
lyzed with the Wilcoxon-Mann-Whitney test. A P value less
than 0.05 was considered a significant difference.
RESULTS
MPA Trough Levels
Of all 4 animals of the control group, theMPA trough level
was under the limit of 0.4 mg/L. The meanMPA trough level
in the MMF20-1 group was 0.5 ± 0.1 mg/L, mean MMF
trough level in the MMF40-1 group was 0.8 ± 0.4 mg/L.
Weight
From the day of the operation, all the animals lost weight
until the third or fourth postoperative day (Figure 1). The
largest weight loss was seen in the group of high-dose MMF
(MMF40): on day 4, the mean weight of the animals was
87.6% from starting point. On days 4, 5, and 6, the weight
in the group MMF 40 was significantly lower compared with
the control group. In each group of high-dose MMF (MMF
40-0 and MMF 40-3), 1 animal died for unknown reason.
Autopsy in both animals revealed distended small bowel,
which may be related to either the operation or the medica-
tion. These animals did not suffer from gastrointestinal signs,
such as diarrhea. During relaparotomy at the end of the exper-
iment, 2 other rats from the MMF 40-0 group, both operated
on day 3, showed signs of ileus, with distended small bowel.
Wound Strength
Individual values for bursting pressure of ileum and colon
anastomoses and their bursting sites (within our outside the
anastomoses) are given in Figure 2. Compared with the con-
trol group, the anastomoses of the ileum were stronger in the
MMF-treated animals. This was significantly so in ileum tis-
sue in both MMF-treated groups (P = 0.034 and 0.048 for
MMF 20 and 40 groups, respectively) after 3 days. For co-
lonic tissue, this was not the case (P = 0.81 and 0.17, respec-
tively). At 7 days, no difference could be noted for any of the
groups (P = 0.2, 0.57, 0.29, and 0.41 for the control group
versus MMF20-0, MMF40-0, MMF20-3-7, and MMF40-
3-7 in ileum anastomoses and 0.71, 0.05, 0.41, and 0.22 in
colon anastomoses, respectively). The number of burst sites
outside the anastomoses is again shown in Figure 3. We only
show here the percentages after 7 days, when in many animals,
the anastomoses have grown stronger than the surrounding
tissue. The number of cases where the bursting takes place
outside the anastomose is not different among the groups.
Breaking strength is shown in Figure 4. Here, the ileum
anastomoses of rats of the MMF 20 and of the MMF 40
group are significantly stronger than those of the control
group (P = 0.014 and 0.041, respectively). After 7 days, no
significant difference is measured (P = 0.072, 0.4, 0.2 and
0.12 for control versus groups MMF20-0, 40-0, 20-3-7,
and 40-3-7, respectively). In colon tissue, no difference can
bemeasured between the control group and the experimental
groups (P = 0.57 and 0.33 at 3 days and 0.42, 0.94, 0.65
and 0.87 at 7 days). In abdominal wall tissue, a decrease of
strength is measured after 7 days in the high-dose experimen-
tal group that was treated from day 0 (MMF40-0), the
P value was 0.022. The low-dose group in this experiment
just failed to show a significant difference but showed the
same trend (P = 0.05). The negative effect disappeared when
the medication was delayed for 3 days. P values at 7 days
were, respectively, 0.41, 0.36, 0.37, and 0.20 for groups
MMF20-0, MMF 20-3-7, MMF 40-3-7, and MMF 40-1-3.
Histology
No obvious architectural differences were seen between
the different groups of the colon tissue or fascia tissue. How-
ever, in the ileum, the accumulation of polymorphonuclear
cells, macrophages, and lymphocytes was more profound in
the control rats than in theMMF20 or 40 rats, indicating less
progress in the healing of the anastomose. Evenmore striking
was the fact that bridging of the mucosa and submucosal
layer seemed to be less advanced in the control rats (Figure 5).
DISCUSSION
The introduction of new immunosuppressive agents in the
last decades has significantly improved the outcome of solid
organ transplantation but this improvement is accompanied
with new adverse effects, such as nephrotoxicity, lymphoceles,
or wound healing disturbances. Wound healing is a very com-
plex process that is potentially influenced by all immunosup-
pressive agents, although this is difficult to assess in clinical
studies, where patients receive a combination of immunosup-
pressant drugs. The problem with most clinical studies is that
wound healing is not a primary endpoint but part of a stan-
dard adverse event listing thatmight be vulnerable to reporting
bias. Compared with the vast amount of studies concerning
FIGURE 1. Postoperative course of body weight. Points represent
average relative body weight, in relation to the weight before opera-
tion, for the control group (+) and the groups receiving MMF 20 (),
MMF 40 (●), MMF 20 with delay (–) and MMF 40 with delay (△).
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transplant survival, few studies or reviews have focused on
wound healing. In 2012, Nanshan21 reviewed the literature of
immunosuppressant agents and wound healing. Herein MMF
does not seem to have a clear benefit over mTOR inhibitors,
although the combination of MMF with mTOR inhibitors
may have an additive negative effect on wound healing, as
concluded from the study of Pengel et al.22
Very few preclinical studies have been carried out in the past
to determine the effect of MMF on wound healing,13,16,17,21
These studies almost unanimously find a negative effect of
FIGURE 3. Data represent the frequency (percentages) of the bursting site outside and inside the actual suture line on day 7. Light gray rep-
resents bursting at the anastomose site in ileum, dark gray represents bursting outside the ileum anastomose. White represents bursting at the
anastomose in colon and black represents bursting outside colon anastomose, all measured at day 7.
FIGURE 2. Anastomotic bursting pressure. Individual values and medians (horizontal lines) in ileum and colon. A, Ileum control group 3 days
postoperative versusMMF 20 and 40; B, colon control group 3 days postoperative versusMMF 20 and 40; C, ileum control group 7 days post-
operative versus MMF 20 and 40 7 days postoperative and at 7 days but after a delay of 3 days; D, colon control group 7 days postoperative
versus MMF 20 and 40 7 days postoperative and at 7 days but after a delay of 3 days. X-axis: study groups. Open symbols denote rupture
outside the suture line and closed symbols rupture inside the suture line. Significant P values are marked with an asterisk.
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MMF. Zeeh et al16 were the first to show a negative effect on
healing of bowel anastomoses in rats on systemic MMF,
started 3 days before surgery. However, in this study, MMF
was administered intraperitoneally, which may have had a
direct effect on the colonic anastomoses and not mimic the
orally administration of human organ recipients.
Mycophenolate mofetil is a “prodrug” which is metabo-
lized in the active MPA, a specific inhibitor of IMPDH. This
is a key enzyme for de novo synthesis of guanosine nucleo-
tides, essential for DNA and RNA synthesis and necessary
for maximum lymphocyte proliferation. The immune sup-
pressant action is therefore based on a decrease of prolifera-
tion of T and B lymphocytes and monocytes. There is also
evidence that MMF inhibits the action of fibroblasts and
other cells that are not part of the immune system.13 A nega-
tive effect of MMF on wound healing is therefore plausible,
evenwhen started postoperatively, as is the case in new trans-
plant recipients.
The experiment presented here is carried out to measure
the effects of MMF on the healing of bowel anastomoses
and abdominal wall after laparotomy. In the first postopera-
tive week, wound strength is relatively low, and chances of
complications are high. To guarantee that no effect of MMF
is missed, 2 timepoints of measurement were incorporated:
3 days postoperative, at the end of the inflammatory phase,
when wound strength is known to be at the weakest point
and 7 days after operation, which is during the proliferation
phase, when the wound strength is increasing rapidly. Myco-
phenolate mofetil is administered orally in 2 different dosages:
20 mg/kg and 40 mg/kg bodyweight. These dosages have
proven to have a sufficient immunosuppressant action in rats
and lead to clinically relevant MPA trough levels.23–25 Two
rats in the high-dose group died prematurely of unknown
reason but did have distended small bowel. This might be re-
lated to the study medication because the therapeutic window
of MMF is narrow. In some preclinical studies, dosages of 40
to 60 mg/kg were not well tolerated by rats.23,24 The weight
loss at 4, 5, and 6 days postoperative was significantly greater
for the animals treated with the highest dose of MMF
(MMF40). This observation is also made by Schuurman
et al,24 where they compared the MMF-CsA combination
with CsA only. Mycophenolate mofetil is known for dose-
dependent gastrointestinal side effects, such as diarrhea,26
but although side effects were recorded, no more cases of di-
arrhea were seen in the experimental groups compared with
the control group. At day 7, the difference between the MMF
40 group and the control group disappeared, thus showing
an adequate recuperation of the rats in the MMF 40 group.
FIGURE 4. Wound breaking strength. Data represent median and
range in all groups. A, ileum; B, colon; C, abdominal wall. P values
that are significant are marked with an asterisk.
FIGURE 5. Histology example of hematoxylin-eosin–stained specimens. A, Ileum anastomose in control rat at 7 days; B, ileum anastomose in
40-0 rat at 7 days. Arrows indicate suture material.
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The results presented here show a positive effect of MMF
on the healing of ileum anastomoses, no effect on the healing
of colon anastomoses and a negative effect when started at
day 0 on the healing of the abdominal wall. Bursting pressure
after 3 days in ileum anastomoses of the MMF treated ani-
mals is significantly higher than that in the control group.
In the measurement of breaking strength in ileum after 3 days
we see a similar pattern. In the colon, no significant difference
in bursting pressure or breaking strength is noted between the
control group and the experimental groups at 3 or 7 days. In
the measurement of bursting pressure, the site of bursting in-
dicates the strength of the anastomoses. After day 3, when
the wound has gained a considerable amount of strength,
the bursting site will often be outside the anastomosis. This
means that the anastomosis has grown stronger than the ad-
jacent tissue, and the measurement itself does not represent
wound strength anymore. However, the rising proportion
of bursting sites outside the anastomosis does indicate an in-
crease in strength. This increase in strength is seen clearly in
all groups comparing day 3 with day 7. Although a trend
is seen toward a decrease in proportion of bursting sites out-
side the anastomoses, particularly in the high-dose groups
(MMF40) and in the delayed low-dose group (MMF20-3),
these differences were not statistically different. The only neg-
ative effect of MMF is seen in the abdominal wall tissue,
where a significant decrease of breaking strength is seen in
the highest-dose group, when the medication was started on
day 0. The negative effect disappeared when the medication
was delayed for 3 days. The abdominal wall model might
therefore be a more sensitive model to wound healing than
the bowel anastomose model.
The data presented here show a diverse effect of MMF on
its own, dependent on the tissue that the effect is measured
in. We have found no published data in the literature on a
different effect of MMF according to tissue, because preclin-
ical effects are usually measured on 1 tissue type only. Limita-
tions of this study are the fact that we do not know if the
dosages used are directly transferable to the human situation.
Although pharmacokinetics in humans and rats are similar,
the dosage of 40 mg/kg may have been too high. Further-
more, as in all animal studies, we do not know if these find-
ings are directly transferable to humans.
CONCLUSIONS
As a single agent in a preclinical wound healing model in
the rat, MMF in high dose has a negative effect on healing
of the abdominal wall, which could possibly be prevented by
delaying the medication for 3 days. No negative effect was
found on the wound healing of bowel anastomoses.
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